Life Care News
A Hope Of True Information

- Advertisement -

Ultragenyx to Present at the 2023 Barclays


NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company’s chief medical officer, will present at the 2023 Barclays – Gene Editing & Gene Therapy Summit on Wednesday, May 24, 2023, at 8:50 a.m. ET.

The live and archived webcast of the panel will be accessible from the company’s website at

- Advertisement -

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

- Advertisement -

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at:

Contacts – Ultragenyx Pharmaceutical, Inc.
Joshua Higa

Jeff Blake

Get real time updates directly on you device, subscribe now.